Literature DB >> 20526192

Preconditioning and postinsult therapies for perinatal hypoxic-ischemic injury at term.

Robert D Sanders1, Helen J Manning, Nicola J Robertson, Daqing Ma, A David Edwards, Henrik Hagberg, Mervyn Maze.   

Abstract

Perinatal hypoxic-ischemic encephalopathy can be a devastating complication of childbirth. Herein, the authors review the pathophysiology of hypoxic-ischemic encephalopathy and the current status of neuroprotective strategies to ameliorate the injury centering on four themes: (1) monitoring in the perinatal period, (2) rapid identification of affected neonates to allow timely institution of therapy, (3) preconditioning therapy (a therapeutic that reduces the brain vulnerability) before hypoxic-ischemic encephalopathy, and (4) prompt institution of postinsult therapies to ameliorate the evolving injury. Recent clinical trials have demonstrated the significant benefit for hypothermic therapy in the postnatal period; furthermore, there is accumulating preclinical evidence that adjunctive therapies can enhance hypothermic neuroprotection. Advances in the understanding of preconditioning may lead to the administration of neuroprotective agents earlier during childbirth. Although most of these neuroprotective strategies have not yet entered clinical practice, there is a significant hope that further developments will enhance hypothermic neuroprotection.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20526192     DOI: 10.1097/ALN.0b013e3181dc1b84

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  26 in total

Review 1.  [Rational use of oxygen in anesthesiology and intensive care medicine].

Authors:  J Meier; O Habler
Journal:  Anaesthesist       Date:  2011-04       Impact factor: 1.041

Review 2.  Cannabinoid as a neuroprotective strategy in perinatal hypoxic-ischemic injury.

Authors:  Daniel Alonso-Alconada; Antonia Alvarez; Enrique Hilario
Journal:  Neurosci Bull       Date:  2011-08       Impact factor: 5.203

3.  Metabotropic actions of the volatile anaesthetic sevoflurane increase protein kinase M synthesis and induce immediate preconditioning protection of rat hippocampal slices.

Authors:  Jun Wang; Fanli Meng; James E Cottrell; Todd C Sacktor; Ira S Kass
Journal:  J Physiol       Date:  2012-06-06       Impact factor: 5.182

4.  Treatment device for neonatal birth asphyxia related Hypoxic Ischemic Encephalopathy.

Authors:  Rediet Zewdie; Lidet Getachew; Geremew Dubele; Ababo Oluma; Gedion Israel; Kokeb Dese; Gizeaddis Lamesgin Simegn
Journal:  BMC Pediatr       Date:  2021-11-03       Impact factor: 2.125

5.  Effect of hyperbaric oxygen on lipid peroxidation and visual development in neonatal rats with hypoxia-ischemia brain damage.

Authors:  Jing Chen; Yan-Hui Chen; Hong-Yan Lv; Li-Ting Chen
Journal:  Biomed Rep       Date:  2016-05-10

6.  ER stress related factor ATF6 and caspase-12 trigger apoptosis in neonatal hypoxic-ischemic encephalopathy.

Authors:  Luran Liu; Chang Liu; Yuting Lu; Lina Liu; Yan Jiang
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

7.  Sevoflurane postconditioning provides neuroprotection against brain hypoxia-ischemia in neonatal rats.

Authors:  Xiaoyan Ren; Zhi Wang; Hong Ma; Zhiyi Zuo
Journal:  Neurol Sci       Date:  2014-04-05       Impact factor: 3.307

8.  Hypobaric hypoxia postconditioning reduces brain damage and improves antioxidative defense in the model of birth asphyxia in 7-day-old rats.

Authors:  Marcin Gamdzyk; Dorota Makarewicz; Marta Słomka; Apolonia Ziembowicz; Elzbieta Salinska
Journal:  Neurochem Res       Date:  2013-11-02       Impact factor: 3.996

Review 9.  Impact of anaesthetics and surgery on neurodevelopment: an update.

Authors:  R D Sanders; J Hassell; A J Davidson; N J Robertson; D Ma
Journal:  Br J Anaesth       Date:  2013-03-29       Impact factor: 9.166

10.  The effects of levosimendan on brain metabolism during initial recovery from global transient ischaemia/hypoxia.

Authors:  Anna B Roehl; Norbert Zoremba; Markus Kipp; Johannes Schiefer; Andreas Goetzenich; Christian Bleilevens; Nikolaus Kuehn-Velten; Rene Tolba; Rolf Rossaint; Marc Hein
Journal:  BMC Neurol       Date:  2012-08-24       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.